stockrowThe Chemours Company
CC Basic Materials Specialty Chemicals
The Chemours Company’s revenue for fiscal 2025 (year ended December 2025) was $5.8 billion, roughly unchanged from fiscal 2024.
- Revenue
- +3.01%
- EPS
- +223.8%
- Free cash flow
- −12.5%
- Total debt
- −7.64%
Quarter to September 2026, against a year earlier
Follow CC
Alert me
The Chemours Company (CC) Total debt
The Chemours Company's total debt at the end of fiscal 2025 was $4.1B, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $3.8B. Over the past ten years it has ranged from $3.5B (fiscal 2016) to $4.2B (fiscal 2019); the current reading is higher than 91% of that period. The Chemours Company ranks 12th of 60 Specialty Chemicals companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $4.1B | 0.68% |
| FY2024 | $4.1B | 1.86% |
| FY2023 | $4.0B | 11.15% |
| FY2022 | $3.6B | (3.09%) |
| FY2021 | $3.7B | (6.88%) |
| FY2020 | $4.0B | (3.22%) |
| FY2019 | $4.2B | 4.73% |
| FY2018 | $4.0B | (3.40%) |
| FY2017 | $4.1B | 16.03% |
| FY2016 | $3.5B | (10.37%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $3.8B | (1.01%) |
| Jun 2026 | $3.9B | (6.41%) |
| Mar 2026 | $4.1B | (0.10%) |
| Dec 2025 | $4.1B | (0.22%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| CC The Chemours Company | $3.8B |
| FUL H. B. Fuller Company compare | $2.1B |
| NGVT Ingevity Corporation compare | $1.1B |
| MTX Minerals Technologies Inc. compare | $957.8M |
| KWR Quaker Houghton compare | $892.0M |
| SCL Stepan Company compare | $341.7M |
| WDFC WD-40 Company compare | $86.0M |
| IOSP Innospec Inc. compare | $42.0M |
| STDN Standard Nuclear Inc compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CC
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement